The Vaping Lung Injury Crisis: What EVALI Taught Us, and What We've Forgotten

In the summer of 2019, emergency rooms across the United States began seeing patients with a presentation that didn't fit any established diagnostic category: young, previously healthy individuals with severe respiratory distress, bilateral lung infiltrates on imaging, and a history of vaping. By February 2020, the CDC had identified 2,807 hospitalized cases and 68 deaths in what it named EVALI—e-cigarette or vaping product use-associated lung injury. The outbreak triggered a nationwide panic, a flurry of state-level vaping bans, and a permanent shift in public perception of vaping safety. Then, in November 2019, the CDC identified the primary cause: vitamin E acetate, a cutting agent used in illicit THC cartridges, not in legal nicotine e-liquids. The outbreak subsided. The panic receded. But the lessons of EVALI—which were specific, important, and directly relevant to ongoing policy debates—have been selectively remembered and selectively forgotten.

The scientific investigation that identified vitamin E acetate as the causative agent was a triumph of coordinated public health response. The CDC, state health departments, and academic laboratories worked together to analyze bronchoalveolar lavage fluid from EVALI patients, comparing it to fluid from healthy controls. Vitamin E acetate was identified in the lung fluid of 48 of 51 EVALI patients and zero of 99 healthy controls—a smoking gun by epidemiological standards. The mechanism was biologically plausible: vitamin E acetate, when inhaled as an aerosol and then cooled in the lungs, reverts to an oily liquid that coats the alveolar surface, disrupting gas exchange and triggering an inflammatory cascade. The outbreak was traced to illicit THC cartridges—primarily obtained from informal sources like friends, dealers, and online marketplaces—that had been cut with vitamin E acetate to increase volume and profit margins. Legal, regulated nicotine e-liquids from licensed retailers were not implicated. The EVALI outbreak was not a vaping crisis. It was an illicit-market crisis that manifested through vaping hardware.

The public understanding of EVALI diverged dramatically from the scientific findings, and this divergence has had lasting consequences for nicotine policy. Surveys conducted after the CDC identified vitamin E acetate as the cause found that a majority of Americans continued to believe that EVALI was caused by nicotine e-cigarettes or were unsure of the cause. The initial messaging—which emphasized the association with 'vaping' without adequately distinguishing between nicotine and THC products, legal and illicit sources—created a durable impression that 'vaping causes lung injury' in the generic sense. This impression has been exploited by advocates of restrictive vaping policies, who cite EVALI as evidence that e-cigarettes are dangerous. It has also created lasting confusion among smokers, who sometimes cite EVALI as a reason not to switch to vaping—a decision that, if it results in continued smoking, has far greater health consequences than the (essentially zero) risk of EVALI from legal nicotine products.

The regulatory response to EVALI was swift, severe, and misdirected relative to the actual cause. Several states, including Massachusetts, Washington, and Rhode Island, imposed emergency bans on flavored nicotine e-liquids—products that had nothing to do with the outbreak. The CDC initially advised all consumers to 'consider refraining from using e-cigarette products' without distinguishing between THC and nicotine or legal and illicit. The Trump administration announced (and then partially walked back) a federal ban on flavored e-liquids. These responses addressed the politically salient product category (nicotine vaping) rather than the causally implicated one (illicit THC cartridges). The disconnect between the evidence and the policy response was not just a failure of communication. It was a demonstration of how crises are exploited to advance pre-existing regulatory agendas, regardless of whether the crisis evidence supports those agendas.

The deeper lesson of EVALI concerns the dangers of unregulated markets—and the extent to which prohibition creates those markets. Vitamin E acetate entered the THC cartridge supply chain because THC cartridges are illegal under U.S. federal law but widely used in states where cannabis is legal in some form. This created a market that was too large to be suppressed by enforcement and too illegal to be regulated for safety. In the absence of product standards, testing requirements, and manufacturing regulations—all of which exist for legal nicotine e-liquids in most developed countries—the illicit THC market became a vector for dangerous adulterants. EVALI was a direct consequence of the regulatory gap created by cannabis prohibition. The same dynamic applies to nicotine where prohibitionist policies are implemented: flavor bans, shipping restrictions, and product prohibitions drive consumers toward illicit sources where product safety is unregulated and adulteration is unmonitored. EVALI was a warning about what happens when products people want are driven into unregulated markets. The warning has been selectively heard.

The most important lessons of EVALI for nicotine policy are straightforward and widely applicable. First: the safety of vaping products depends overwhelmingly on the regulatory framework in which they're produced, not on the product category itself. Legal, regulated nicotine e-liquids were not the cause of EVALI, and regulated markets with product standards, ingredient disclosure, and manufacturing quality controls are the primary defense against future outbreaks. Second: communication about health risks must be precise about the specific products, sources, and behaviors involved—generic warnings about 'vaping' cause more harm than good when they conflate products with radically different risk profiles. Third: prohibition creates unregulated markets, and unregulated markets create health risks that are far more severe than the risks of regulated products. EVALI was the predictable result of a prohibited product (THC cartridges) being consumed through the same hardware as a legal product (nicotine e-liquids), with the resulting health crisis misattributed to the legal product. This pattern—prohibition creating harm, harm being blamed on the legal alternative—is precisely what harm-reduction advocates warn will happen if nicotine products are regulated prohibitively rather than proportionately.

The EVALI outbreak has receded from headlines, but its lessons remain urgently relevant. Every jurisdiction debating vaping flavor bans, nicotine product prohibitions, or restrictions on legal access should be required to answer a question: what will happen to the demand this policy doesn't eliminate, and who will control the supply that meets that demand? The vitamin E acetate that killed 68 people entered the market through precisely the kind of unregulated channel that prohibition creates. The legal nicotine market, for all its imperfections, did not cause those deaths. The distinction between regulated and unregulated, legal and illicit, is not incidental to public health—it's the central variable. EVALI taught us that. The question is whether we'll remember it the next time a crisis—or a policy response—threatens to erase the distinction.